ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
CSPC will receive an upfront payment of $100 million from AstraZeneca
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Subscribe To Our Newsletter & Stay Updated
